课题基金 / 基金详情

IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA

IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA
IDEC Y2B8 放射免疫疗法与 Rituxan 治疗复发 B 细胞淋巴瘤的比较
批准号:
6304166
负责人:
Leo I. Gordon
金额:
$2.05万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-01 至 2000-11-30

项目摘要

项目成果

Leo I. Gordon的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项随机、III期、多中心、对照研究,比较了晚期、复发或难治性非霍奇金b细胞淋巴瘤患者单疗程的IDEC-Y2B8和一个疗程的Rituxan的疗效和安全性。一个疗程的IDEC-Y2B8包括影像学剂量的IDEC-In2B8,一周后单剂量的IDEC-Y2B8;IDEC-Y2B8和IDEC-In2B8之前均输注250 mg/m2 Rituxan。利妥昔单抗一个疗程包括4次375 mg/m2输注(每周一次× 4)。低级别或滤泡性NHL复发或常规化疗失败且现在需要治疗的患者将符合本研究的条件。符合研究纳入和排除标准的患者可以被纳入研究。
英文摘要
This is a randomized, Phase III, multi-center, controlled study comparing the efficacy and safety of a single course of IDEC-Y2B8 with a course of Rituxan in patients with advanced, relapsed or refractory non-Hodgkin's B-cell lymphoma. A course of IDEC-Y2B8 includes an imaging dose of IDEC-In2B8 followed one week later by a single dose of IDEC-Y2B8; both IDEC-Y2B8 and IDEC-In2B8 are preceded by an infusion of 250 mg/m2 Rituxan. A course of Rituxan includes four infusions of 375 mg/m2 (once weekly x 4) of Rituxan. Patients with low-grade or follicular NHL who have relapsed disease or have failed primary conventional chemotherapy and now require treatment will be eligible for this study. Patients meeting the study inclusion and exclusion criteria may be enrolled into the study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 RADIOIMMUNOTHERAPY IN B CELL NON HODGKINS LYMPHOMA
IDEC Y2B8 RADIOIMMUNOTHERAPY FOR NON HODGKINS LYMPHOMA AFTER RITUXIMAB
IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA
MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
海外基金